Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhuo http://orcid.org/0000-0001-6696-8282
Luo, Lin
Xing, Chuan
Chen, Yu http://orcid.org/0000-0002-2037-7337
Xu, Peng http://orcid.org/0000-0001-8007-9879
Li, Mao
Zeng, Ling
Li, Chao
Ghosh, Sadashib http://orcid.org/0000-0001-6874-8814
Della Manna, Deborah
Townes, Tim
Britt, William J.
Wajapeyee, Narendra
Sleckman, Barry P. http://orcid.org/0000-0001-8295-4462
Chong, Zechen
Leavenworth, Jianmei Wu http://orcid.org/0000-0002-4100-9883
Yang, Eddy S. http://orcid.org/0000-0002-6450-2638
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-18-1-0315, W81XWH-19-1-0084)
U.S. Department of Health & Human Services | National Institutes of Health (R01AI148711)
American Association for Cancer Research (15-20-43-YANG)
Autotec, Inc. Breast Cancer Research Foundation of Alabama
- License Information
-
More Information
Article History
Received: 3 April 2020
Accepted: 25 August 2021
First Online: 22 October 2021
Competing interests
: E.S.Y. is a consultant for AstraZeneca, Eli Lilly and Company and is on the Advisory Board for Bayer Pharmaceuticals, AstraZeneca, Clovis Oncology and Strata Oncology. The research in the laboratory of E.S.Y. is supported by funding from Novartis International AG, Eli Lilly and Company, Clovis Oncology and the American Society of Clinical Oncology. The remaining authors declare no competing interests.
